trial · primary record
Ami-LC-MD
Neoplasms
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 158 |
| Primary completion | 2027-04-01 |
| Primary endpoint | Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) |
| Registry ID | NCT04606381 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:43.140Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04606381
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.